Logo Valence
Populaire
Se connecter
Loading data for IVA — first visit, this takes a few seconds.

Ajouter à la liste de suivi

Inventiva S.A.

NasdaqGM: IVA · Prix en temps réel · USD
4.60
+0.00 (0.00%)
À la clôture : Aug 14, 2026, 8:00 PM

Inventiva S.A. (IVA) Stock Price, Analysis & Data

0.00%

Aucune donnée disponible

Cours acheteurn/a
Capitalisation boursière1.09B
Chiffre d’affaires (ttm)6.76M
Résultat net (ttm)-354.14M
Bêta0.91
EPS (ttm)-2.19
Ratio P/E (ttm)n/a
P/E prévisionnel-5.52
P/B (ttm)-26.95
P/S (ttm)160.72
Earnings DateSep 25, 2026
Cours vendeurn/a
Volume572,947
Volume moy. (20D)1,008,014
Ouverture4.63
Clôture précédente4.60
Fourchette du jour4.54 - 4.65
Intervalle de 52 semaines3.35 - 7.98
Analysten/a
Objectif de prixn/a
Dividendesn/a
Date ex-dividenden/a

À propos de IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of pat...

[En savoir plus]
Industrie Biotechnology
Secteur Healthcare
Date d’introduction Jul 10, 2020
Employés 69
Bourse NasdaqGM
Symbole boursier IVA
Site web https://inventivapharma.com
Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Inventiva S.A. s’élevait à 4.48M, soit une baisse de -51.26% par rapport aux 9.2M de l’année précédente. Le bénéfice s’élevait à -354.14M, soit une hausse de 92.24%.

États financiers

Surprise sur les résultats

Inventiva S.A. a publié ses résultats trimestriels le Mar 10, 2022 :
  • Chiffre d’affaires de n/a est inférieur aux estimations de $0, avec NaN% croissance en glissement annuel.
  • EPS de -0.16 dépasse les estimations de 0.23, avec -Infinity% Baisse en glissement annuel.

    • Prochaine publication des résultats

    Inventiva S.A. devrait publier ses résultats le Sep 25, 2026, après la fermeture du marché.
    Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure
    news image

    1 mois il y a · Insider Monkey

    Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring

    Inventiva S.A. (NASDAQ:IVA) is one of the best strong buy penny stocks to invest in now. Inventiva S.A. (NASDAQ:IVA) announced on July 9 the completion of the final step of the transactions previously...

    news image

    1 mois il y a · Simply Wall St.

    Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound

    Inventiva (ENXTPA:IVA) stock has been relatively flat in the latest session, leaving investors focused on how its clinical stage pipeline in MASH and rare diseases, together with recent share performa...

    news image

    1 mois il y a · MT Newswires

    European Equities Traded in the US as American Depositary Receipts Rise Thursday

    European equities traded in the US as American depositary receipts were rising on Thursday morning,

    news image

    1 mois il y a · Insider Monkey

    Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside

    Inventiva S.A. (NASDAQ:IVA) is one of the 10 best stocks under $10 offering more than 50% upside. As of the June 24 close, Inventiva S.A. (NASDAQ:IVA) had a strongly bullish consensus sentiment. The s...

    news image

    1 mois il y a · Zacks

    After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)

    Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates ...

    Page 1 de 2